NRx Pharmaceuticals (Nasdaq: NRXP) to Present Keynote Address on Ketamine Efficacy and Risks at Upcoming Sachs Neuroscience Innovation Forum in San Francisco

https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaq-nrxp-to-present-keynote-address-on-ketamine-efficacy-and-risks-at-upcoming-sachs-neuroscience-innovation-forum-in-san-francisco-302024326.html

RADNOR, Pa., Jan. 2, 2024 /PRNewswire/ — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, (NRx), a clinical-stage biopharmaceutical company today announced that it has been selected to give the keynote address entitled “Ketamine for Suicidal Depression: The Benefits are Clear, But So are the Risks,” at the upcoming Sachs Neuroscience Innovation Forum in San Francisco, CA on January 7, 2024. The Company plans to file a New Drug Application for Ketamine in 2024, both in the United States and the European Union in partnership with the Fondation FundaMental of Paris, FR.

Read more at prnewswire.com

Related news for (NRXP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.